AbbVie arthritis med meets late-stage study goal

Jun 05, 2018

AbbVie's experimental drug upadacitinib met its goal of stopping progression of moderate-to-severe rheumatoid arthritis in a late-stage trial. It was tested as a monotherapy in patients who have not been treated with methotrexate, a chemotherapy agent.

The med is a JAK inhibitor, which work by blocking inflammation-causing enzymes known as Janus kinases. AbbVie is planning to submit a U.S. marketing application in the second half of 2018.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments